Journal ArticleDOI
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
William E. Klunk,Henry Engler,Agneta Nordberg,Yanming Wang,G. Blomqvist,Daniel P. Holt,Mats Bergström,Irina Savitcheva,Guo Feng Huang,Sergio Estrada,Birgitta Ausén,Manik L. Debnath,Julien Barletta,Julie C. Price,Johan Sandell,Brian J. Lopresti,Anders Wall,Pernilla Koivisto,Gunnar Antoni,Chester A. Mathis,Bengt Långström +20 more
Reads0
Chats0
TLDR
The results suggest that PET imaging with the novel tracer, PIB, can provide quantitative information on amyloid deposits in living subjects.Abstract:
This report describes the first human study of a novel amyloid-imaging positron emission tomography (PET) tracer, termed Pittsburgh Compound-B (PIB), in 16 patients with diagnosed mild AD and 9 controls. Compared with controls, AD patients typically showed marked retention of PIB in areas of association cortex known to contain large amounts of amyloid deposits in AD. In the AD patient group, PIB retention was increased most prominently in frontal cortex (1.94-fold, p = 0.0001). Large increases also were observed in parietal (1.71-fold, p = 0.0002), temporal (1.52-fold, p = 0.002), and occipital (1.54-fold, p = 0.002) cortex and the striatum (1.76-fold, p = 0.0001). PIB retention was equivalent in AD patients and controls in areas known to be relatively unaffected by amyloid deposition (such as subcortical white matter, pons, and cerebellum). Studies in three young (21 years) and six older healthy controls (69.5 +/- 11 years) showed low PIB retention in cortical areas and no significant group differences between young and older controls. In cortical areas, PIB retention correlated inversely with cerebral glucose metabolism determined with 18F-fluorodeoxyglucose. This relationship was most robust in the parietal cortex (r = -0.72; p = 0.0001). The results suggest that PET imaging with the novel tracer, PIB, can provide quantitative information on amyloid deposits in living subjects.read more
Citations
More filters
Journal ArticleDOI
Novel chalcones as probes for in vivo imaging of β-amyloid plaques in Alzheimer’s brains
TL;DR: The results in this study suggest that the novel radioiodinated chalcones may be useful amyloid imaging agents for detecting beta-amyloid plaques in the brain of AD.
Journal ArticleDOI
Cerebrospinal fluid biomarkers of Alzheimer’s disease
Anne M. Fagan,David M. Holtzman +1 more
TL;DR: The most promising cerebrospinal fluid biomarkers are summarized, novel applications and current challenges are highlighted, and a prediction on how the field may evolve in 5-10 years is provided.
Journal ArticleDOI
The Frontal Assessment Battery Does Not Differentiate Frontotemporal Dementia from Alzheimer’s Disease
Stefania Castiglioni,Oriana Pelati,Marta Zuffi,Francesco Somalvico,Lorenza Marino,Tiziana Tentorio,Massimo Franceschi +6 more
TL;DR: The Frontal Assessment Battery does not differentiate patients with AD from those with FTD, like all other executive tests, however, it may be useful in the examination of executive function in AD, FTD and several other pathological conditions.
Journal ArticleDOI
The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11–labeled Pittsburgh compound B
Patrick J. Lao,Tobey J. Betthauser,Ansel T. Hillmer,Julie C. Price,William E. Klunk,Iulia Mihaila,Andrew T. Higgins,Peter Bulova,Sigan L. Hartley,Regina M. Hardison,Rameshwari V. Tumuluru,Dhanabalan Murali,Chester A. Mathis,Annie Cohen,Todd E. Barnhart,Darlynne A. Devenny,Marsha R. Mailick,Sterling C. Johnson,Benjamin L. Handen,Bradley T. Christian +19 more
TL;DR: In Down syndrome (DS), the overproduction of amyloid precursor protein is hypothesized to predispose young adults to early expression of Alzheimer‐like neuropathology.
Journal ArticleDOI
α4β2 nicotinic receptor status in Alzheimer’s disease using 123I-5IA-85380 single-photon-emission computed tomography
John T. O'Brien,Sean J. Colloby,Sanjeet Pakrasi,Elaine K. Perry,Sally L. Pimlott,David J. Wyper,Ian G. McKeith,E D Williams +7 more
TL;DR: Changes consistent with significant reductions in the nicotinic α4β2 receptor in cortical and striatal brain regions are found using single-photon-emission CT (SPECT) using 123I-5-iodo-3-[2(S)-2-azetidinylmethoxy] pyridine (5IA-85380).
References
More filters
Journal ArticleDOI
Clinical diagnosis of Alzheimer's disease : report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
Guy M. McKhann,David A. Drachman,Marshall F. Folstein,Robert Katzman,Donald L. Price,Emanuel M. Stadlan +5 more
TL;DR: The criteria proposed are intended to serve as a guide for the diagnosis of probable, possible, and definite Alzheimer's disease; these criteria will be revised as more definitive information becomes available.
Journal ArticleDOI
Neuropathological stageing of Alzheimer-related changes.
Heiko Braak,Eva Braak +1 more
TL;DR: The investigation showed that recognition of the six stages required qualitative evaluation of only a few key preparations, permitting the differentiation of six stages.
Journal ArticleDOI
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data:
TL;DR: A theoretical model of blood–brain exchange is developed and a procedure is derived that can be used for graphing multiple-time tissue uptake data and determining whether a unidirectional transfer process was dominant during part or all of the experimental period.
Journal ArticleDOI
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
TL;DR: Aβ-deposition in the entire brain follows a distinct sequence in which the regions are hierarchically involved and expands anterogradely into regions that receive neuronal projections from regions already exhibiting Aβ.
Journal ArticleDOI
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations:
TL;DR: General equations are derived that can be used to analyze tissue uptake data when the blood–plasma concentration of the test substance cannot be easily measured and for situations when trapping of theTest substance is incomplete and for a combination of these two conditions.
Related Papers (5)
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann,Guy M. McKhann,David S. Knopman,Howard Chertkow,Bradley T. Hyman,Clifford R. Jack,Claudia H. Kawas,William E. Klunk,Walter J. Koroshetz,Jennifer J. Manly,Richard Mayeux,Richard C. Mohs,John C. Morris,Martin N. Rossor,Philip Scheltens,Maria C. Carrillo,Bill Thies,Sandra Weintraub,Creighton H. Phelps +18 more